Articles tagged "Immunosuppression"

2016 American Transplant Congress
Therapeutically Equivalent Results to Caucasians in Black Kidney Transplant Recipients Using ASTAGRAF XL^® Despite a Higher Degree of HLA Mismatch : A Post-Hoc Analysis of Phase III Data from Over 2000 Patients.
J. Schwartz, S. Wilson, F. Shi, N. Undre, M. Kumar.
Astelleas Pharma Global Develepment, Northbrook, IL.
INTRO: When contemplating the use of a new immunosuppressant agent in kidney transplantation, measuring outcomes in potentially vulnerable populations is of paramount concern. As such,…
2016 American Transplant Congress
Does Post-Transplant Adherence Come at a Cost?
K. Yadav, T. Nevins, D. Vock, W. Thomas, W. Robiner, A. Matas.
University of Minnesota, Minneapolis, MN.
Background: It is well documented that organ transplant (tx)recipients have an increased incidence of cancer including virus associated cancers like lymphoma. Our objective was to…
2016 American Transplant Congress
Mycophenolic Acid Product Discontinuation Prior to Conception: Analysis of Pregnancies in Kidney Transplant Recipients.
S. Constantinescu,^1,2 L. Coscia,² D. Armenti,² M. Moritz.^2,3
¹Medicine, Temple University, Philadelphia, PA; ²Gift of Life Institute, National Transplantation Pregnancy Registry (NTPR), Philadelphia, PA; ³Surgery, Lehigh Valley Health Network, Allentown, PA.
Mycophenolic acid (MPA) products are considered teratogenic and transplant centers report discontinuing MPA in female kidney recipients anticipating pregnancy. Data were collected by the National…
2016 American Transplant Congress
Avoidance of CNI and Steroids Using Belatacept – A Preliminary Report of CTOT-16.
R. Mannon,¹ P. Stock,² A. Mehta,³ D. Ikle,⁴ N. Watson,⁵ N. Bridges,⁵ M. Robien,⁵ K. Newell.³
¹UAB, Birmingham; ²UCSF, San Francisco; ³Emory, Atlanta; ⁴Rho, Chapel Hill; ⁵NIAID, Bethesda.
CTOT-16 tested the hypothesis that belatacept used as maintenance immunosuppression (IS) in kidney transplantation would allow the long-term avoidance of CNI and corticosteroids. Methods: Primary…
2015 American Transplant Congress
Favorable Results of ABO Incompatible Renal Transplantation Without B Cell Targeted Therapy: Advantages and Disadvantages of Rituximab Pretreatment
M. Okada,¹ K. Futamura,¹ K. Itou,¹ T. Yamamoto,¹ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ S. Narumi,¹ Y. Watarai,¹ A. Katayama,² K. Uchida,³ T. Kobayashi.⁴
¹Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Masuko Memorial Hospital, Nagoya, Japan; ³Aichi Medical University, Nagakute, Japan; ⁴Nagoya University School of Medicine, Nagoya, Japan.
INTRODUCTIONThe outcome of ABO-incompatible transplantation (ABO-I) has been reported to be comparable to that of ABO-identical/compatible transplantation (ABO-Id/C), which is considered to be due to…
2015 American Transplant Congress
Final Results from the BENEFIT-EXT Trial: A 7 Year Follow-Up of Belatacept Treated Patients
S. Florman,¹ J. Medina Pestana,² M. Rial,³ L. Rostaing,⁴ D. Kuypers,⁵ F. Mühlbacher,⁶ M. Polinsky,⁷ U. Meier-Kriesche,⁷ J. Grinyó,⁸ A. Durrbach.⁹
¹Mt Sinai Med Ctr, NY; ²Hosp do Rim e Hipertensão, Sao Paulo, Brazil; ³Inst de Nefrologia, Buenos Aires, Argentina; ⁴Univ Hospital, Toulouse, France; ⁵Univ Hospital Leuven, Leuven, Belgium; ⁶Vienna Transplantation Ctr, Vienna, Austria; ⁷BMS, Lawrenceville; ⁸Univ Hosp Bellvitge, Barcelona, Spain; ⁹Univ Hosp of Bicêtre, Villejuif, France.
Background: At 3 and 5yrs post-transplant, BENEFIT-EXT showed a renal function benefit and consistent safety in belatacept (bela) treated pts vs cyclosporine (CsA). Final 7…
2015 American Transplant Congress
Effect of Intrapatient Variability and Mean Tacrolimus Levels in Renal Transplant Patients
D. Goodall, M. Willicombe, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
IntroductionNonadherence (NA) to immunosuppressive medication and adherence to immunosuppressive protocols is a potent risk factor for rejection and graft loss, which can be both patient…
2015 American Transplant Congress
Efficacy and Safety of Once-Daily Everolimus With Minimized Once-Daily Tacrolimus After Liver Transplantation
P. De Simone,¹ P. Carrai,¹ L. Coletti,¹ A. Precisi,² D. Campani,³ F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy; ²Laboratory, University of Pisa Medical School Hospital, Pisa, Italy; ³Pathology, University of Pisa Medical School Hospital, Pisa, Italy.
Background: The everolimus (EVR) pharmacokinetic profile allows for its once daily (OD) administration. We tested the efficacy and safety of a combination schedule of OD-EVR…
2015 American Transplant Congress
Emerging Application of Active Immune Targeted Delivery in Transplantation
M. Uehara,¹ A. Jamil,¹ M. McGrath,¹ Z. Solhjou,¹ N. Banouni,¹ S. Tullius,² C. Jianjun,³ R. Abdi.¹
¹Renal Division, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical Shcool, Boston, MA; ²Division of Transplant Surgery, Brigham and Women's Hospital, Boston, MA; ³Materials Science and Engineering, University of Illinois at Urbana-Champaign, Champaingn, IL.
Targeted nanodelivery has created enormous excitement as a transformative approach to deliver therapeutics to tissues of interest. In recent years, we have made significant progress…
2015 American Transplant Congress
Interleukin-17A Induced Human Mesenchymal Stem Cells Are Superior Modulators of Immunological Function
K. Sivanathan,^1,2,3 D. Rojas-Canales,^1,2 S. Grey,⁵ C. Hope,^1,2 R. Carroll,^1,4 S. Gronthos,^3,6 P. Coates.^1,2,3,4
¹Centre for Clinical and Experimental Transplantation, Royal Adelaide Hospital, Adelaide, South Australia, Australia; ²School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia; ³Centre for Stem Cell Research, Robinson Institute, University of Adelaide, Adelaide, South Australia, Australia; ⁴Central Northern Adelaide Renal Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia; ⁵Transplantation Immunology Group, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; ⁶Mesenchymal Stem Cell Laboratory, School of Medical Sciences, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia.
Interferon-gamma preactivated mesenchymal stem cells (MSC-γ) are highly immunosuppressive but immunogenic in vivo due to their inherent expression of major histocompatibility (MHC) molecules. We modified…